Gestalt Diagnostics Announces Advisory Board Formation with Leading Industry Experts
Gestalt Diagnostics has created an Advisory Board led by their Medical Director, Dr. David Hoak. The board consists of Pathologists who have extensive backgrounds in leading edge technology, regulatory expertise and a focus on emerging technologies such as digital pathology.
Advisory board members include:
Dr. Bruce Beckwith, pathologist and Chairman of Pathology at North Shore Medical Center in Salem, MA with an
appointment in Pathology at Massachusetts General Hospital in Boston, MA. Dr. Beckwith serves as the College of
American Pathologists (CAP) liaison to the DICOM Pathology Working Group (WG-26) and was a founding co-chair of
that group. He has also been a member of multiple informatics related committees of the CAP and is currently a member
of the CAP Digital Pathology committee. In addition to his interests in standards development and pathology imaging,
Dr. Beckwith has collaborated on informatics research projects related to making de-identified pathology data and
archival material available for research using a peer to peer networking architecture. When asked about joining the
Gestalt Diagnostics Advisory Board Dr. Beckwith said “I am very excited to work with the team at Gestalt to help inform
the development of software tools that will make it easier for pathologists to adopt digital pathology.”
Dr. Eric Glassy, a community pathologist in Southern California and director of pathology at Providence Little Company
of Mary Medical Center, San Pedro. He is a member of Affiliated Pathologists Medical Group, a 40 person independent
pathology group covering 15 hospitals and laboratories in California, Portland and Phoenix. Dr. Glassy has won a number
of pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of
American Pathologists (CAP). He has chaired hospital and CAP national committees. He served as chairman of the
Hematology and Clinical Microscopy Resource, Publications, Digital Pathology and Curriculum Committees. He is a past
Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is past president of the
Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software
programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma. He is a trustee
of the American Board of Pathology as well as a board member of the CAP. “I am happy to participate in helping Gestalt
roll out their meaningful and impactful digital pathology solution”, says Dr. Glassy.
Dr. John Spinosa, M.D., Ph.D. is the Chief Medical Officer at the San Diego Blood Bank. Dr. Spinosa has a broad
background in clinical and anatomic pathology, hematology, molecular diagnostics and informatics. He spent 20 years at
Scripps Memorial Hospital as Medical Director, Chief of Staff and Chair of Pathology, and has extensive experience in
hospital-based general surgical pathology. He is also entrepreneurial, serving as CMO/Medical Director of local clinical
laboratories at Lexent Bio, Avera, Trovagene, Verinata Health, Prometheus, Esoterix Oncology and other specialty labs.
Dr. Spinosa says, "I look forward to engaging with Gestalt Diagnostics to help provide useful, functional products for the
practicing pathologist that can facilitate the incorporation of whole slide imaging into routine clinical practice. Providing
improved tools is essential in keeping pathology practice vibrant for health systems, physician clients, and patients."
Dr. David Hoak, Gestalt Medical Director, says, "I am pleased and excited that Drs. Eric Glassy, John Spinosa and Bruce
Beckwith are joining the scientific advisory board of Gestalt Diagnostics. Their expertise in informatics and digital
pathology will help refine and improve Gestalt's digital pathology products that seek to improve pathologists' workflow
and efficiency. "
Gestalt Diagnostics is a private, profit-driven software company who has developed PathFlow, an enterprise software
platform specifically designed to bring the benefits of digital workflow to pathologists and pathology
laboratories. This product was originally developed, by what is now Gestalt’s team, to support a fully digital
reading platform for radiology. The radiology platform is used in leading hospitals across the United States and
supports more than 15 million studies annually. Gestalt has expanded and redesigned this proven, robust
solution to work in the laboratory space – engineered for the unique needs and workflow of pathologists.

Spokane, Washington, July 9, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, showcased its AI-powered pathology platform, PathFlow, at the Spring 2025 DICOM WG-26 Interoperability Connectathon, confirming its readiness for real-world clinical integration and multi-vendor environments. The Connectathon was co-sponsored by the Digital Pathology Association (DPA) and the European Society of Digital and Integrative Pathology (ESDIP). The event, hosted virtually from January to June and featured at the European Congress on Digital Pathology in Barcelona, brought together over 30 organizations to validate end-to-end workflows, in varying categories, using DICOM standards. The categories included image acquisition, storage, viewing, and AI-driven annotations. Gestalt’s platform stood out as a leader in interoperability, particularly as an Image Display (Viewer). Gestalt’s Viewer successfully displayed images from 8 of 9 different WSI Scanners, demonstrating seamless compatibility with multiple diverse systems such as 3DHISTECH, Grundium, Leica, Hamamatsu and Pramana. This robust performance ensures pathologists can access high-quality whole slide images effortlessly, regardless of the source, streamlining diagnostic workflows. Additionally, PathFlow excelled in displaying annotations from five AI Evidence Creators, including industry leaders like Visiopharm, Hologic, TechCyte and identify.bio, further demonstrating its ability to present structured data for precise diagnostic insights. As an Evidence Creator itself, (AI Annotations), Gestalt showcased its advanced AI capabilities, by analyzing and annotating images from eight scanners. These annotations were successfully transmitted to five different image management archives using standard DICOM Web protocols, highlighting Gestalt’s ability to deliver accurate, standards-compliant AI-driven outputs. This functionality empowers pathologists to integrate AI seamlessly into routine clinical operations, improving efficiency and diagnostic accuracy. “Gestalt’s performance at the Connectathon reflects our dedication to building interoperable, scalable solutions that empower pathologists globally,” said Brian Napora, VP of Innovation, Gestalt Diagnostics. “By investing in open standards, we’re helping lead digital pathology toward a more integrated and intelligent future.” The Connectathon’s rigorous testing environment validated Gestalt’s ability to handle real-world challenges, such as legacy image integration and complex multi-vendor workflows without requiring custom workarounds. Gestalt’s commitment to DICOM standards positions PathFlow as a cornerstone for vendor-neutral, future-ready pathology solutions. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

Spokane, Washington, June 17, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, today announced the addition of Dr. Renuka Kulkarni, MD, as Chief Medical Officer (CMO). A physician scientist with over 20 years of experience in surgical and digital pathology, Dr. Kulkarni will join the team in guiding Gestalt’s product direction and clinical usability. Dr. Kulkarni brings a rare blend of diagnostic precision and scientific innovation to the organization. Her expertise in breast pathology, immunomarkers, machine learning, and image analysis strengthens Gestalt’s mission to revolutionize diagnostic workflows and clinical decision-making through technology. “Renuka’s addition signals our deepening investment in the future of pathology,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “Her leadership and experience at the intersection of clinical insight, AI, and enterprise lab operations will ensure our solutions continue to serve both pathologists and the patients they care for.” Before joining Gestalt, Dr. Kulkarni played a pivotal role in developing one of the earliest digital pathology programs at a leading full-service reference laboratory. Her extensive hands-on experience with Gestalt’s solutions, as a customer and direct user for four years, along with image analysis platforms, and combined with her understanding of real-world lab operations, positions her to help bridge the clinical and commercial realms—ensuring the scalability and impact of Gestalt’s solutions. As CMO, Dr. Kulkarni will help shape the development of next-generation diagnostic tools, supporting Gestalt’s mission to enhance diagnostic accuracy, efficiency, and interoperability across health systems worldwide. “I’m honored to join Gestalt at such a transformative moment in digital pathology,” said Dr. Kulkarni. “Together, we have the opportunity to shape solutions that truly serve pathologists and ultimately improve outcomes for patients everywhere.” About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

Date : Wednesday, May 21, 2025 Time : 1:45 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Session Title : The Long-Term Advantages of Digital Pathology are Only Realized Through True Interoperability We’re proud to announce that Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, and Sumie Edwards (ARUP) will take the stage at the 2025 Pathology Informatics Summit to share key insights into the critical role of interoperability in digital pathology. In this featured session, Lisa-Jean will explore: Why interoperability is the linchpin for scalable, future-ready digital pathology programs How health systems can unlock long-term value and efficiency through seamless integration Real-world considerations for IT infrastructure, workflow design, and cross-platform compatibility Her session will offer a strategic lens into how institutions can achieve meaningful digital transformation, not just implement new tools. About the PI Summit : The Pathology Informatics Summit is a premier annual event for professionals at the forefront of digital pathology, laboratory medicine, AI, and healthcare data innovation. It brings together leading physicians, researchers, and informaticists to discuss the rapidly evolving field. Mark your calendar for May 21 at 1:45 PM to hear Lisa-Jean share her vision for a more connected and impactful future in pathology.

Date : Thursday, May 22, 2025 Time : 9:00 AM – 12:00 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Panel Title : API Focus Session: Expert Panel on LDT Regulation Overhaul and Data Challenges in Pathology Informatics Join Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, for an important panel discussion at the 2025 Pathology Informatics Summit alongside top voices in the field of pathology informatics. This focus session will dive into: The impact of the FDA’s Final Rule on Laboratory Developed Tests (LDTs) Data governance, standardization, and access challenges for AI in pathology The urgent need for broadly sourced datasets to support the next generation of clinical AI models Panel Moderator : Ulysses Balis, MD Expert Panelists : Victor Brodsky, MD – Washington University School of Medicine, St. Louis Lisa-Jean Clifford – Gestalt Diagnostics Bruce Friedman, MD Ronald Jackups, MD, PhD – Washington University School of Medicine, St. Louis Amrom Obstfeld, MD, PhD – Children’s Hospital of Philadelphia Michelle Stoffel, MD, PhD – University of Minnesota J. Mark Tuthill, MD – Henry Ford Health System This dynamic session includes two panel discussions followed by open Q&A: The FDA’s Final Rule on LDTs The Growing Crisis of Limited AI Training Data in Pathology Why it matters : With regulatory landscapes shifting and AI innovation surging, this session offers a rare chance to hear from experts shaping the future of diagnostics, data ethics, and clinical technology adoption. Don’t miss this opportunity to learn from Lisa-Jean and fellow leaders who are building the next chapter of pathology informatics.

Spokane, Washington, April 28, 2025 – Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a $7.5 million Series A financing. The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest. Gestalt’s PathFlow® platform is used by leading healthcare, academic medical centers, and research organizations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. "PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise." This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company’s customer base, enhance AI capabilities, and pursue FDA clearance. This comes at a critical moment, with rising cancer rates and a declining number of practicing pathologists intensifying the need for scalable, digital-first diagnostic solutions. “We are incredibly grateful for the continued support from our investors,” Roark added. “This funding allows us to expand on the solid foundation we’ve built. We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.” Gestalt is at the forefront of a critical shift in diagnostic medicine, helping transform pathology from a manual, microscope-based process to a scalable digital solution leveraging artificial intelligence tools — like the digital transitions already seen in radiology and cardiology. The company’s platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable: Biomarker scoring to support the optimization of patient-therapy matching, Image and data analysis for disease progression studies, And the interoperability that enables pathologists access to valuable aides and insights that streamline their workflows, highlight areas of positivity and reduce missed diagnoses. With this Series A funding, Gestalt remains committed to expanding its impact through the deployment of its’ PathFlow software in healthcare, making high-quality, scalable pathology solutions more accessible to clinicians and researchers worldwide. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

March 21, 2025 – Mumbai, India and Spokane, Washington – AIRA Matrix, a leading innovator in AI-driven QC solutions, and Gestalt, an industry leader in IMS and digital pathology, have formed a strategic partnership to bring AIRA Matrix’s advanced AI solution, AIRAQC, to Gestalt's PathFlow. This collaboration marks a significant step toward enhancing diagnostic precision and efficiency in laboratories worldwide. AIRAQC, powered by cutting-edge artificial intelligence, streamlines quality control processes, enabling faster and more accurate analysis in pathology workflows. By integrating AIRAQC with Gestalt's workflows, pathologists will gain access to a seamless, AI-enhanced experience designed to optimize diagnostic decision-making. "We're thrilled to partner with Gestalt to expand the reach of AIRAQC and deliver transformative AI capabilities to pathology labs," said Marco Comianos, Head of Commercial Operations - US., AIRA Matrix. "This collaboration is a testament to our shared commitment to advancing pathology through innovation." “The partnership between AIRA Matrix and Gestalt represents a continued effort to drive progress in pathology by leveraging technology to meet evolving healthcare needs. Together, our companies aim to empower laboratories with state-of-the-art tools that improve diagnostic accuracy, quality and meaningful metrics from the start of the diagnostic process” says Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. About AIRA Matrix: Delivers artificial intelligence solutions for healthcare and life sciences applications. Our innovative products and services drive efficiency, enhance diagnostic accuracy, and provide data-driven insights from digitally scanned images. Our comprehensive AI-driven suite for drug discovery and development, streamlines pre-analytical quality control, facilitates tissue triage, and optimizes safety and efficacy assessments, accelerating breakthrough discoveries. Our healthcare portfolio offers diagnostic, prognostic, and predictive tools that facilitate risk stratification and enable personalized therapy planning, thus improving treatment outcomes., visit www.airamatrix.com. About Gestalt Diagnostics: Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable experience where it matters most. *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.